1-2 of 2
Vincent O'Neill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Fred R. Hirsch, Marileila Varella-Garcia, Rafal Dziadziuszko, Yun Xiao, Sujatha Gajapathy, Margaret Skokan, Ming Lin, Vincent O'Neill, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6317–6323.
https://doi.org/10.1158/1078-0432.CCR-08-0539
Published: 30 September 2008
View articletitled, Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
Open the PDF for Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer in another window
Journal Articles

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard, Guy Cavet, Wenjing Zhu, Ling Fu, Thinh Q. Pham, Robert Soriano, Jeremy Stinson, Somasekar Seshagiri, Zora Modrusan, Chin-Yu Lin, Vincent O'Neill, Lukas C. Amler
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8686–8698.
https://doi.org/10.1158/1078-0432.CCR-05-1492
Published: 16 December 2005
View articletitled, Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Open the PDF for Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients in another window